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Induction of a mucosal immune response is generally thought to require introduction of an immunogen directly onto the
mucosal surface. It has been observed, however, that live, attenuated mutants of the alphavirus, Venezuelan equine encepha-
litis virus (VEE), induce protection from virulent challenge at the respiratory mucosa even after parenteral inoculation. In
this report, we propose a mechanism by which subcutaneous immunization with a molecularly cloned, attenuated double
mutant of VEE is able to stimulate the production of mucosal anti-VEE IgA. Our results showed that the immunizing virus
spread to, and replicated within, lymphoid tissues throughout the mouse. Several tissues known to be inductive sites of the
mucosal immune system were found to be positive for the presence of VEE RNA by 48 hr postimmunization. Moreover,
this mucosal lymphotropism resulted in the production of virus-specific IgA antibody detectable in vaginal secretions of
immunized mice. q 1997 Academic Press
INTRODUCTION typic change from wild type (Grieder et al., 1995). As
was the case for all of the recombinant vaccine candi-
Venezuelan equine encephalitis virus (VEE) is a mem- dates tested, V3014 showed greatly reduced virulence
ber of the alphavirus genus, family Togaviridae, a group in mice, hamsters, and horses and induced solid pro-
of viruses that cause disease in humans and other verte- tection against a high dose parenteral challenge with
brates (Peters and Dalrymple, 1990). In the natural set- virulent VEE (Davis et al., 1991; Smith and Johnston,
ting, alphaviruses are transmitted by arthropod vectors. unpublished observations).
An infectious dose is delivered by the bite of an infected Virulent VEE delivered to mice by aerosol or intrana-
mosquito, which can be mimicked experimentally by sub- sal inoculation replicates within the nasal mucosa and
cutaneous inoculation (Turrel and Spielman, 1992; Turrel within olfactory sensory neurons located there. The
et al., 1995). VEE is unusual among alphaviruses in that virus invades the brain rapidly by anterograde spread
it also can spread via aerosol transmission, which makes of virus down the axons of the chemosensory olfactory
it a significant hazard to laboratory and veterinary work- neurons (Charles et al., 1995; Ryzhikov et al., 1991,
ers. Therefore, one goal in the design of a VEE vaccine 1995). Vaccination with vaccinia vectors expressing
is to protect against both parenteral and aerosol routes VEE glycoproteins protects mice against parenteral,
of infection. but not against intranasal challenge with virulent VEE
We have constructed a series of VEE-derived cDNA (Kinney et al., 1988). A formaldehyde-inactivated VEE
clones in which selected attenuating mutations, identi- vaccine also is protective against parenteral, but not
fied in biological isolates, were combined (Davis et al., against aerosol challenge in hamsters (Jahrling and
1989, 1991; Johnston and Smith, 1988). Transcription Stephenson, 1984). Live, attenuated VEE vaccines,
of such clones in vitro yielded infectious RNA genome however, generally provide protection from aerosol
equivalents from which the cognate series of VEE vac- and/or intranasal challenge (Davis et al., 1995; Jahrling
cine candidates was derived. V3014 is one of these and Stephenson, 1984; Kinney et al., 1988).
candidates. It contains two attenuating mutations in Antigen presentation within the mucosal associated
the surface glycoprotein genes, a change from the pa- lymphoid tissue is thought to be critical for the produc-
rental Glu at E2 209 to Lys, and a change from the tion of protective secretory IgA antibody (Lange et al.,
parental Ala at E1 272 to Thr, as well as a third change, 1980; Liang et al., 1988; Nedrud et al., 1987; Weisz-
from Ile to Asn at E2 239, resulting in no known pheno- Carrington et al., 1979, 1987). Once presented in an
inductive site, IgA specific for the antigen is found at
mucosal surfaces throughout the mouse. In most1 To whom correspondence and reprint requests should be ad-
cases, delivery of the immunogen to a mucosal surfacedressed at present address: Department of Pathology (Neuropathol-
is a prerequisite for uptake into one of the mucosal-ogy), F520, Albert Einstein College of Medicine, 1300 Morris Park Ave.,
Bronx, NY 10461. associated lymphoid tissues. At least one such site,
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the Peyer’s patch, has been implicated in the pathology ileum containing Peyer’s patches, and sections of rectal
tissue containing perirectal lymph nodes were dissectedof VEE in hamsters (Gorelkin and Jahrling, 1975).
Therefore, we tested the hypothesis that subsequent and processed for histological examination and ISH. Na-
sal tissues were examined by decalcification of wholeto subcutaneous immunization with V3014, the virus
itself or V3014-infected cells are targeted to a mucosal heads, followed by sectioning and embedding, as pre-
viously described (Charles et al., 1995; Davis et al., 1996).IgA inductive site(s). In this report we demonstrate (1)
that subcutaneous inoculation with a recombinant VEE All animal experimentation was performed in accordance
with National Institutes of Health guidelines. All animalvaccine candidate, V3014, results in targeted replica-
tion within inductive sites of the mucosal immune sys- protocols were approved by the animal care and use
committee of the University of North Carolina at Chapeltem, (2) that this mucosal lymphotropism results in the
production of mucosal IgA specific for VEE, and (3) Hill.
that the immune response to V3014 can protect mice
Cellsagainst intranasal challenge with virulent virus. While it
is not yet clear which specific elements of the immune BHK-21 cells were obtained from ATCC in the 53rd
response to V3014 are involved in the protection af- passage and maintained in Eagle’s minimum essential
forded to animals immunized with this virus, mucosal medium (EMEM) supplemented with 10% donor calf se-
anti-VEE IgA is an appealing candidate. rum, 10% tryptose phosphate broth, 0.29 mg/ml L-gluta-
mine, 0.5 mg/ml streptomycin, and 100 units/ml penicillin.
Cells were used from passage 55 to 65.MATERIALS AND METHODS
Mice Virus
Stocks of VEE virus were produced as described pre-Five-week-old female CD-1 mice were obtained from
Charles Rivers Laboratories (Wilmington, MA). Mice were viously (Davis, 1989; Grieder, 1995). Briefly, the plasmids
pV3000 and pV3014, containing full-length viral cDNAs,maintained in a BL-3 laboratory in barrier cages with
sterile bedding, water, and standard mouse chow (ad were linearized with NotI, and runoff RNA transcripts
were produced with T7 RNA polymerase. RNA transcriptslibitum). All mice were allowed to acclimatize in the BL-
3 laboratory for at least 1 week prior to undergoing any were introduced into BHK-21 cells by electroporation
(Davis et al., 1996). Tissue culture supernatants wereprocedure. Mice were inoculated by injection of virus
diluted in PBS plus 1% donor calf serum (PBS-DCS) into harvested at 24 hr when CPE was maximal, and virus
was quantitated by standard plaque assay on BHK-21the left rear footpad while under light Metophane anes-
thesia. Mice were sacrificed at the time points indicated cells. Working stocks of virus were prepared by dilution
of supernatants into phosphate-buffered saline con-in the figure legends and perfused transcardially with
100 ml of ice-cold 4% paraformaldehyde in PBS, pH 7.2. taining 1% donor calf serum (PBS-DCS), to give a final
concentration of 105 PFU/ml. Working stocks were frozenIpsilateral popliteal lymph node, mandibular lymph node,
mesenteric lymph node, spleen, thymus, five sections of in 0.20-ml aliquots at 0707 until used.
FIG. 1. CD-1 mice were inoculated in the left rear footpad with either 104 PFU of V3014 or V3000 in 10 ml of diluent or diluent alone (mock
immunized). Tissues for in situ hybridization were harvested at 24 and 48 hr. All controls for ISH were uniformly negative. Viral signal was detected
in the draining (ipsilateral popliteal lymph node) of V3014- and V3000-infected mice at 24 hr (A and B, respectively). VEE signal in the draining
lymph node was more widespread in the V3000-infected mice, being present in subcapsular cortical areas, medullary, and paracortical regions.
Examination of hematoxylin- and eosin-stained serial sections revealed severe liquefactive necrosis in draining lymphnodes of V3000-infected
animals (D), but which was not seen in the V3014-infected mice (C). At 48 hr, viral RNA was detectable in the Peyer’s patches of both V3014 (E)
and V3000 (F) infected mice, as well as in the perirectal lymph nodes (G, V3014; H, V3000). In contrast to draining lymph nodes (A and B), viral
RNA was confined to paracortical and medullary areas of gut-associated lymphoid tissues. Original magnification 251 in A, B, E, F, G, H; 631 in
C and D.
FIG. 2. Six-week-old female CD-1 mice were immunized subcutaneously in the left rear footpad with a dose of 1 1 103 PFU of V3014 in 10 ml of
PBS-DCS or PBS-DCS alone (mock immunized). Seven weeks after immunization, mice were challenged with virulent virus by instilling 10 ml of
PBS-DCS containing 104 PFU of V3000 into each nostril. Mice were mock challenged by instillation of 10 ml of PBS-DCS alone into each nostril. At
24, 48, and 72 hr postchallenge, mice were sacrificed, perfused with 4% paraformaldehyde in PBS, pH 7.2, and nasal olfactory tissues were removed
and prepared for histopathology and ISH. Negative controls included mock-immunized/mock-challenged and immunized/mock-challenged mice
probed with the VEE-specific riboprobe, and mock-immunized/mock-challenged, mock-immunized/challenged, immunized/mock-challenged, and
immunized/challenged mice probed with an irrelevant riboprobe (influenza HA glycoprotein specific). Two slides, each with tissue from five levels
within the olfactory system, were examined for each group (3 mice per group). All controls were uniformly negative by ISH. Histopathologic
appearance of hematoxylin and eosin (H/E) sections of all mock-challenged mice were normal. (A) Characteristic lesions were present within the
olfactory neuroepithelium of mock-immunized/challenged mice at 72 hr postchallenge. Focal necrosis with concomitant structural disorganization
across the full thickness of the olfactory mucosa was present at 24 hr postchallenge and became essentially confluent by 72 hr. (B) Areas of
histopathology were positive for the presence of viral RNA as detected by ISH. (C) Immunized mice showed no evidence of histopathological change
at 72 hr postchallenge. (D) There was no viral RNA detectable by ISH in immunized mice at 72 hr postchallenge. Bar represents 25 mm (A, C) or
100 mm (B, D).
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TABLE 1
Immunization with V3014 Results in the Production of Both Serum IgG and Mucosal IgA Antibody
Vaginal IgA Serum IgG
Day 10 Day 14 Day 21 Day 49 Day 49
Mock 1:2 1:2 1:2 1:2.5 { 0.86* 1:50 { 0**
Immunized 1:16 1:64 1:32 1:9 { 4.4* 1:28,666 { 15,216**
Note. Anti-VEE vaginal IgA and serum IgG ELISA titers in CD-1 mice immunized with V3014 or mock immunized with diluent as described in the
legend of Fig. 1. Titers of anti-VEE vaginal IgA titers for Days 10, 14, and 21 were determined on pools of 16 mice. Day 49 anti-VEE IgA titer is the
mean of 4 pools of 4 mice each. Day 49 titers for serum anti-VEE IgG are the mean of titers of 16 individual mice. Day 49 titers are expressed as
mean titer { standard deviation. Significance of Day 49 vaginal IgA and serum IgG as determined by Student’s t test: *P  0.04; **P  2.7 1 1009.
ELISA for anti-VEE antibody nt radiolabeled RNA probe complementary to the 3* end
of the virus message sense RNA (6K and E1 genes). The
Sucrose gradient-purified VEE virions were diluted into
negative control construct produced an approximately
carbonate buffer (100 mM NaHCO3 , pH 9.6), and 250 ng 500-nt riboprobe complementary to the influenza (strain
of protein in a volume of 50 ml was evaporated in each
PR-8) hemagglutinin mRNA. Incorporation of a[35S]UTP
well of an Immulon-4 microassay plate (Dynatech). Vaginal
was typically 80 – 95% and was quantitated by liquid scin-
washes were performed by flushing the vaginal introitus
tillation counting. Probes were hybridized to 3-mm paraf-with 75 ml of sterile PBS. Wash fluids for a given day were
fin sections that had been mounted on aminopropyl
pooled in groups of 4 or 16 mice, concentrated 10-fold in
triethoxysilane-coated slides (ProbeOn Plus, Fisher Sci-
Centricon-100 microconcentrators, and analyzed by ELISA
entific). Hybridization and wash conditions were as pre-
as described (Olmstead et al., 1986). Mouse serum or vagi-
viously described (Grieder et al., 1995; Charles et al.,
nal wash fluid was diluted into PBS/3% ovalbumin and ana-
1995). Slides were dipped in Kodak NTB-2 emulsion,
lyzed for the presence of IgM, -G, -G1, -G2a , and -A class dried, and exposed at 0707 for 24 to 144 hr. Following
antibodies using horseradish peroxidase-conjugated,
development, slides were counter-stained with Gill’s he-
class-specific anti-mouse goat serum (Sigma). The sub-
matoxylin.
strate was o-Phenylenediamine (OPD, Sigma), and reac-
tions were stopped by addition of 0.1 M NaF. The ab-
RESULTSsorbance was read at 450 nm on a Dynatech MR4000
automated microplate reader. Titers are reported as the
Spread of V3014 to peripheral lymphoid tissuehighest dilution to give an ODA450 of 0.200.
The spread of V3014 and the virulent parent virus,
In situ hybridization (ISH)
V3000, to peripheral lymphoid tissues of the mouse fol-
Probes for VEE structural genes and the influenza HA lowing subcutaneous inoculation was examined. Follow-
gene (negative control) were generated as previously ing a single dose of 104 PFU of V3014 or V3000 delivered
described (Grieder et al., 1995; Charles et al., 1995). subcutaneously into the left rear footpad, peripheral
Briefly, a pGEM-3 clone containing the 993-bp PstI– SacI lymphoid tissues were analyzed 24 and 48 hr later for
fragment (nt 9,493– nt 10,486) of pV3000 was linearized the presence of VEE RNA by ISH. Both V3000 and V3014
at the unique SmaI site. In vitro Sp6 polymerase tran- were present in the draining popliteal lymph node at 24
scription reactions containing a[35S]UTP produced a 678- hr (Figs. 1A and 1B). Replication of V3000 was more
extensive and was accompanied by severe necrosis
(Figs. 1C and 1D). Necrosis was primarily liquifactive,
TABLE 2 although apparently apoptotic cells were also present.
Immunization with V3014 Protects against Intranasal These data agree well with previous experiments with
Challenge with Virulent V3000 these viruses (Grieder et al., 1995). Hybridization signal
was detectable first in the subcapsular, cortical areas of
Route of V3000
the lymph node, consistent with entry via the afferentchallenge Diluent inoculated V3014 inoculated
lymphatics. By 48 hr, RNA from both V3000 and V3014
100% mortality (2/2) was detectable in spleen, Peyer’s patches (Figs. 1E and
Intraperitoneal 0% mortality (0/2)
AST  7.5 days 1F), mesenteric lymph nodes, mandibular lymph nodes,
100% mortality (6/6) and the perirectal lymph nodes (Figs. 1G and 1H). RNAIntranasal 0% mortality (0/8)
AST  7.7 { 1.1 days from V3000, but not V3014, was found in the thymus at
48 hr pi (data not shown). In all of the lymphoid tissuesNote. Deaths per total are shown in parentheses. AST represents
the average survival time of mice that died. beyond the draining lymph node, viral RNA was confined
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largely to paracortical and medullary areas, suggesting 104 PFU of V3000. Challenged mice were sacrificed at
24, 48, and 96 hr postchallenge, and viral spread wasviral entry via the high endothelial venules or capillaries.
determined by plaque assay of serum, olfactory, and neu-
Anti-VEE antibody levels in V3014-immunized mice ral tissue. Additionally, paired tissue samples were har-
vested to test for evidence of viral replication by ISH andAntibody response to V3014 vaccination is brisk and
histopathology.includes a mucosal component. Following immunization
The outcome of the virulent virus challenge was dra-of mice with 104 PFU of V3014 in the left rear foot pad,
matically different in the V3014- and mock-immunizedantibody levels in the sera and vaginal secretions were
mice. Mock-immunized mice had challenge viral titersdetermined by ELISA. Titers of anti-VEE serum IgG anti-
exceeding 105 PFU of virus per gram of tissue for serumbody ranged from 1:4,000 to 1:64,000 (mean, 1:28,666) at
and all tissues examined, consistent with previous exper-21 days postimmunization and remained at these levels
iments (Charles et al., 1995; Ryzhikov et al., 1991, 1995).for at least 7 weeks (Table 1). Subtyping of antibody
However, in the V3014-immunized animals, the challengeresponse to VEE revealed that essentially all of the anti-
virus was not detectable by plaque assay at any timeVEE IgG antibody produced by the mice was of the IgG2a
point in the olfactory neuroepithelium, olfactory bulbs,subtype (data not shown), indicating a predominantly TH-
brain, or serum of any of the V3014-immunized mice1 type response. No anti-VEE reactivity was detected in
(level of detection was 170 PFU/g of tissue). In the mock-sera from mock-vaccinated mice at a minimum dilution
immunized mice, histopathologic examination revealedof 1:50. ELISA for the presence of anti-VEE IgA antibody
extensive necrosis across the full thickness of the olfac-in mucosal secretions was performed on pooled, concen-
tory mucosa (Fig. 2A), consistent with previously obtainedtrated vaginal washes obtained at 10, 14, 21, and 49 days
results (Charles et al., 1995; Ryzhikov et al., 1991, 1995).pi (Table 1). A strong mucosal antibody response was
In tissue sections of these mice, degenerative changespresent on Days 10, 14, and 21 and peaked at a titer of
also were seen in the olfactory bulbs and lateral olfactory1:64. By 49 days postimmunization, vaginal IgA titers
tracts, indicative of viral spread to the central nervouswere still detectable but had fallen to a range of 1:4
system (data not shown). In situ hybridization analysisto 1:16 (mean, 1:9). Mock-vaccinated controls showed
showed that necrotic areas of the olfactory neuroepithe-background vaginal anti-VEE IgA titers of 1:2.5 or below,
lium were strongly positive for VEE RNA (Fig. 2B). Inwhich remained unchanged throughout the observation
contrast, tissues harvested from V3014-immunized miceperiod.
revealed no evidence of VEE-induced histopathology
(Fig. 2C) and no evidence of viral replication by ISH (Fig.Protection of V3014-immunized mice against
2D). These results indicate that in immunized mice, mini-intranasal VEE challenge
mal if any replication of the challenge virus occurred at
Mice were immunized with a single dose of 103 PFU the mucosal site of inoculation, and suggest that the
of V3014, inoculated subcutaneously into the left rear challenge virus may have been neutralized at the muco-
footpad in a volume of 10 ml, or mock immunized with sal surface by the action of secretory IgA antibody and/
10 ml of diluent. Daily observation of the mice for the first or transudated humoral antibody.
14 days postimmunization revealed no signs of illness.
Three weeks after immunization, the animals were chal-
DISCUSSIONlenged with 104 PFU of virulent V3000 intranasally or
intraperitoneally (challenge dose represents approxi- The demonstration of V3014 replication in sites associ-
mately 500 lethal doses of virus intranasally and 10,000 ated with the induction of a secretory IgA response pro-
lethal doses subcutaneously). No mortality was observed vides a likely explanation for the ability of V3014 to induce
among the V3014-immunized mice after either challenge, VEE-specific mucosal IgA after a parenteral inoculation.
nor did any of these mice display clinically detectable Induction of secretory IgA is thought to require the direct
signs of illness (Table 2). As in numerous prior experi- introduction of antigen onto a mucosal surface, either
ments, the mock-immunized, challenged mice displayed respiratory, digestive, or reproductive (Holmgren, 1991;
the characteristic signs of murine VEE disease, including Liang et al., 1988). Once antigen has been presented at
ruffled fur and lethargy on Day 3, with hind limb paralysis one of these sites, secretory IgA antibody production
progressing to prostration and death between the sixth ensues at most mucosal surfaces, implying the presence
and eighth days postchallenge. of a common mucosal immune system (Holmgren, 1991;
Svennerholm et al., 1980; Weisz-Carrington et al., 1979,
Replication of challenge virus in immunized mice
1987). Conversely, introduction of immunogens at sites
other than the mucosal surface usually does not induceSensitive techniques for measurement of virus growth
in vivo were used to determine the step in challenge a protective mucosal response. For example, intraperito-
neal inoculation of mice with an inactivated influenzavirus replication that was inhibited in the immune mice.
Mice were immunized or mock immunized as previously vaccine failed to protect the nasal mucosa against repli-
cation of challenge influenza virus administered intrana-described and challenged intranasally 7 weeks later with
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sally, while intranasal or intrajejunal immunization with et al., 1995), and the localization of viral replication
around high endothelial venules where circulatinga vaccinia construct expressing the HA gene did afford
protection of the nasal mucosa (Meitin et al., 1991, 1994). lymphoid and myeloid cells may enter the lymphoid tis-
sues, suggest that the virus may move to these tissuesIt has been shown, however, that boosting from a paren-
teral site is capable of stimulating an anamnestic sIgA in a cell-associated form. The identity of a putative hom-
ing cell type, and whether V3014 infects such cells orresponse in humans with preexisting mucosal immunity
(Svennerholm et al., 1980). In the case of parenterally merely adsorbs to them, are active areas of inquiry.
The targeting of attenuated VEE vaccines to lymphoidadministered VEE, a replicating virus is delivered to in-
ductive mucosal sites from the bloodstream rather than tissue generally, and to mucosal-associated lymphoid
tissue in particular, suggests that these viruses mayfrom the mucosal surface. Although VEE administered
subcutaneously enters the inductive pathway for a secre- serve as excellent vaccine expression systems for immu-
nization against mucosal pathogens such as human im-tory IgA response from a different direction, the down-
stream events in the pathway, e.g., the induction of IgA munodeficiency virus. To that end, V3014 has been con-
figured as a replication-competent vector for expressionitself, appear to be similar to those observed with immu-
nogens delivered to mucosal surfaces. Indeed, when an- of heterologous antigens by inserting a duplicate sub-
genomic promoter downstream of the structural genesother live attenuated VEE vaccine candidate, V3526
(Davis et al., 1995), was administered by aerosol to BALB/ (Davis, 1996; N. L. Davis, K. W. Brown, and R. E. Johnston,
unpublished observations). Subcutaneous inoculation ofc mice, 100% of the animals had detectable anti-VEE
IgA in vaginal washes and were completely protected a VEE vector containing the influenza hemagglutinin (HA)
gene resulted in the expression of HA in the drainingagainst aerosol challenge with virulent virus (Hart, un-
published observations). lymph node and protection of mice from disease follow-
ing intranasal challenge with virulent strains of eitherIn the present study we demonstrate the ability of this
vaccine candidate to provide protection of the airway influenza virus or VEE (Davis et al., 1996). Significant
reduction of influenza challenge virus replication in themucosa of the mouse from virulent virus challenge.
Whether this protection is due to the presence of secre- nasal epithelia of HA vector-immunized mice suggested
an active anti-influenza immunity at the mucosal surface.tory IgA within the upper respiratory tract is not yet
known. In preliminary studies, we have been unable to Therefore, the demonstration of protection against both
homologous and heterologous mucosal challenge sug-detect anti-VEE IgA antibody in nasal washes from
V3014-immunized animals (data not shown). Whether this gests that VEE vaccine vectors will be an important alter-
native vaccination strategy against mucosal pathogensrepresents a true failure of the animals to produce IgA
within the respiratory tract or simply a lack of sensitivity when killed or subunit vaccines are ineffective or when
the use of a live attenuated vaccine might be unsafe.of the assay is unknown at this point. However, the find-
ing that the immunizing virus invades and replicates
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